



Coverage of any medical intervention discussed in a WellFirst Health medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and to applicable state and/or federal laws.

Electric Tumor Treatment Field (Optune)

MP9474

Covered Service: Yes

**Prior Authorization
Required:** No

**Additional
Information:** Must be ordered by an Oncology specialist.

WellFirst Health Medical Policy:

- 1.0 Electric Tumor Treatment Field (ETTF) therapy **does not require** prior authorization and is considered medically necessary for adults 22 years of age and older when **EITHER** of the following criteria is met:
 - 1.1 ETTF for the treatment of newly diagnosed, histologically-confirmed supratentorial glioblastoma following debulking surgery and completion of radiation therapy, in conjunction with chemotherapy (temozolomide); **OR**
 - 1.2 ETTF is utilized as monotherapy for persons with histologically confirmed glioblastoma (World Health Organization grade IV astrocytoma), after histologically or radiologically confirmed recurrence in the supratentorial region of the brain after surgical chemotherapy, and radiologic treatment have been exhausted.
- 2.0 The use of devices to generate ETTF for the treatment of other malignant tumors (e.g. breast, lung, melanoma, ovarian cancer, pleural mesothelioma, pancreatic cancer, salivary gland tumors and solid tumor brain metastases – not an all-inclusive list) is considered experimental and investigational and therefore are not medically necessary.



Coverage of any medical intervention discussed in a WellFirst Health medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and to applicable state and/or federal laws.

| | Committee/Source | Date(s) |
|------------------|---|-------------------|
| Document | | |
| Created: | Medical Policy Committee/Health Services Division | February 20, 2019 |
| Revised: | Medical Policy Committee/Health Services Division | June 17, 2020 |
| | Medical Policy Committee/Health Services Division | June 16, 2021 |
| | Medical Policy Committee/Health Services Division | June 15, 2022 |
| | Medical Policy Committee/Health Services Division | February 15, 2023 |
| | Medical Policy Committee/Health Services Division | June 21, 2023 |
| Reviewed: | Medical Policy Committee/Health Services Division | February 19, 2020 |
| | Medical Policy Committee/Health Services Division | June 17, 2020 |
| | Medical Policy Committee/Health Services Division | June 16, 2021 |
| | Medical Policy Committee/Health Services Division | June 15, 2022 |
| | Medical Policy Committee/Health Services Division | February 15, 2023 |
| | Medical Policy Committee/Health Services Division | June 21, 2023 |

Published: 07/01/2023

Effective: 07/01/2023